BioCardia, Inc. Common Stock (BCDA) Stock Price
BCDAStock
$0.92−36.54%52W
Market Cap$13.93M
P/E—
PEG Ratio—
Div yield—
Beta0.64
BCDA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-31.93%
Price vs S&P 500 (4W)-13.48%
VGM Score32.43
BCDA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.19 | -$0.13 | +31.58%(+$0.06) | |
| Q1 2026 | -$0.17 | -$0.21 | -23.53%(-$0.04) | |
| Q4 2025 | -$0.20 | -$0.06 | +70.00%(+$0.14) | |
| Q3 2025 | -$0.25 | -$0.24 | +4.00%(+$0.01) | |
| Q2 2025 | -$0.50 | -$0.40 | +20.00%(+$0.10) |
BCDA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.13
4.13
4.13
4.13
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
BCDABioCardia, Inc. Common Stock | D | F | C | 32.3x | — | 100.0% | — | $0.92 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About BioCardia, Inc. Common Stock
BioCardia is a clinical-stage company developing cell-based therapeutics for cardiovascular and pulmonary diseases with unmet medical needs. Its CardiAMP platform delivers autologous mononuclear cells derived from bone marrow to treat ischemic heart failure with reduced ejection fraction and refractory angina, while its CardiALLO platform uses off-the-shelf allogeneic mesenchymal stem cells for ischemic heart failure and acute respiratory distress syndrome. CardiALLO is currently enrolling patients in clinical trials.